RxDoctor Payments Data

Hans Barthel, MD

Rheumatology · Santa Barbara, CANPI 1003827999

Payments from drug & device makers

$164,106in general payments, 2019–2025

Across 616 payments — averaging $266.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$77K
  • GRT US Holding, Inc.$37K
  • Ultragenyx Pharmaceutical Inc.$17K
  • E.r. Squibb & Sons, L.L.C.$13K
  • AbbVie$11K
  • Amgen$6K
  • plus $4K from 17 others
$3,567in research payments, 2019–2025

Across 2 payments — averaging $1783.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

What the payments were for

  • Consulting fees$11,40040%
  • Speaking & faculty fees$1,6006%
  • Travel & lodging$3,45012%
  • Food & beverage$11,76541%
  • Education$2141%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,106 in reported general payments places this provider in the 85th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$115,671
Medicare patients
188
Services billed
4,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept93$694,292
RinvoqUpadacitinib57$351,886
Xeljanz XrTofacitinib Citrate35$191,906
Humira(Cf) PenAdalimumab24$155,647
OlumiantBaricitinib27$110,586
HumiraAdalimumab11$72,629
BenlystaBelimumab14$68,042
Orencia ClickjectAbatacept12$61,774
OxycontinOxycodone Hcl11$7,570
Hydroxychloroquine Sulfate46$3,516
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$3,369
MethotrexateMethotrexate Sodium95$2,956
Prednisone147$1,374
Raloxifene Hcl25$1,085
Oxycodone Hcl43$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$11,127$424,51568 claims
Lilly USA, LLCOlumiant$467$110,58627 claims
GSKBenlysta$1,058$68,04214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 rheumatology providers in California.

Other rheumatology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →